抗血管生成药物阿帕替尼改善肿瘤免疫微环境的研究进展  

Combination of anti-angiogenic therapy Apatinib and immune therapy potentiate tumor microenvironment

作　　者：高纯一 胡天惠[1] GAO Chun-yi;HU Tian-hui(Cancer Research Center,School of Medicine,Xiamen University,Xiamen,Fujian 361102)

机构地区：[1]厦门大学医学院,福建厦门361102

出　　处：《赣南医学院学报》2021年第5期437-443,共7页JOURNAL OF GANNAN MEDICAL UNIVERSITY

摘　　要：以PD-1/PD-L1的抗体等为代表的免疫治疗已成为肿瘤治疗的重要手段,然而单一疗法在临床应用中获益的患者仅占少数。近年来,越来越多的研究与临床试验发现小分子抗血管生成靶向药物阿帕替尼与PD-1/PD-L1抗体的联合用药能有效提升免疫治疗疗效,其机制与肿瘤微环境的重塑密切相关。本文我们详述临床前及临床试验中抗血管生成剂阿帕替尼对免疫细胞抗肿瘤功能的影响,从免疫微环境角度解释了联合治疗的基本原理。Tumor immune therapy,especially anti-programmed cell death ligand-1/programmed cell death-1(PD-L1/PD-1)treatment,is currently the focus of substantial attention.However,despite its enormous successes,the overall response rate of cancer immunotherapy remains suboptimal.There is an increased interest in combining PD-L1/PD-1 treatment with anti-angiogenic drug Apatinib to enhance antitumor effect.Presently available data seem to suggest that Apatinib may exert immune suppressive effects to make the PD-L1/PD-1 treatment works.Here,we review the extensive tumor microenvironment immune modulatory effects from antiangiogenic agents Apatinib in order to supporting VEGFR2 targettherapies in clinical trials are existing.

关 键 词：阿帕替尼 肿瘤微环境 PD-1/PD-L1 肿瘤免疫治疗 

分 类 号：R730.51[医药卫生—肿瘤]